Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy

Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion

(2016) Wei Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

(2014) Brad S. Kahl et al.   JOURNAL OF CLINICAL ONCOLOGY

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C

(2013) A K Erbe et al.   Journal for ImmunoTherapy of Cancer

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

(2011) A. Curti et al.   BLOOD

IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study

(2011) Claudia Brehm et al.   PLoS One

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

(2010) Melissa A. Geller et al.   CYTOTHERAPY

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

Safety analysis ofex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study

(2009) Lisbeth Barkholt et al.   Immunotherapy

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

(2008) S. Cooley et al.   BLOOD

Up on the tightrope: natural killer cell activation and inhibition

(2008) Lewis L Lanier   NATURE IMMUNOLOGY